Transient receptor potential vanilloid 1 (TRPV1) is expressed widely in the central nervous system and is activated by various stimuli. Inhibiting TRPV1 has neuroprotective effects in cerebral ischemia. The role of inhibiting TRPV1 to maintain blood–brain barrier (BBB) integrity after traumatic brain injury (TBI) remains unclear, however. Therefore, we investigated the effects of capsazepine-mediated TRPV1 inhibition on the BBB in a mouse model of TBI. Adult male C57BL/6 mice underwent controlled cortical impact injury and received capsazepine (1 μmol/kg body weight, twice daily, intraperitoneally) until sacrifice. Further, mouse brain microvascular endothelial (bEnd.3) cells were cultured and underwent biaxial stretch injury to investigate the mechanisms underlying the protective effects of capsazepine. The TRPV1 expression was upregulated in the pericontusional area after TBI, peaking at 24 h post-TBI. Capsazepine-treated mice demonstrated decreased brain edema (p = 0.010), Evans Blue extravasation (p = 0.001), tissue hemoglobin levels (p = 0.002), and loss of tight junction proteins (p = 0.016 ZO-1 expression; p = 0.013 occludin expression) after TBI compared with the vehicle-treated group. Capsazepine significantly alleviated early-stage apoptosis by attenuating activation of JNK, P38, and caspase-3, resulting in a protective effect on the level of ZO-1 in bEnd.3 cells after stretch injury. We conclude that the expression of TRPV1 is upregulated after TBI, and inhibition of TRPV1 attenuated disruption of the BBB in a mouse model of TBI, at least partly, through its antiapoptotic effects on brain endothelial cells. Blocking TRPV1 may be a promising pharmacotherapeutic intervention to protect against BBB disruption after TBI.
Get full access to this article
View all access options for this article.
References
1.
WatanitanonA., LyonsV.H., LeleA.V., KrishnamoorthyV., ChaikittisilpaN., ChandeeT., and VavilalaM.S. (2018). Clinical epidemiology of adults with moderate traumatic brain injury. Crit. Care Med. 46, 781–787.
2.
BrazinovaA., RehorcikovaV., TaylorM.S., BuckovaV., MajdanM., PsotaM., PeetersW., FeiginV., TheadomA., HolkovicL., and SynnotA. (2016). Epidemiology of traumatic brain injury in Europe: a living systematic review. J. Neurotrauma. Epub ahead of print.
3.
RoozenbeekB., MaasA.I., and MenonD.K. (2013). Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 9, 231–236.
4.
RubianoA.M., CarneyN., ChesnutR., and PuyanaJ.C. (2015). Global neurotrauma research challenges and opportunities. Nature, 527, S193–S197.
5.
MajdanM., PlancikovaD., MaasA., PolinderS., FeiginV., TheadomA., RusnakM., BrazinovaA., and HaagsmaJ. (2017). Years of life lost due to traumatic brain injury in Europe: a cross-sectional analysis of 16 countries. PLoS Med. 14, e1002331.
6.
YooD., MagsamA.W., KellyA.M., StaytonP.S., KievitF.M., and ConvertineA.J. (2017). Core-cross-linked nanoparticles reduce neuroinflammation and improve outcome in a mouse model of traumatic brain injury. ACS Nano, 11, 8600–8611.
7.
WernerC. and EngelhardK. (2007). Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99, 4–9.
8.
RuiQ., NiH., GaoF., DangB., LiD., GaoR., and ChenG. (2018). LRRK2 Contributes to secondary brain injury through a p38/Drosha signaling pathway after traumatic brain injury in rats. Front. Cell. Neurosci. 12, 51.
9.
KimC., ParkJ.M., KongT., LeeS., SeoK.W., ChoiY., SongY.S., and MoonJ. (2018). Double-injected human stem cells enhance rehabilitation in TBI mice via modulation of survival and inflammation. Mol. Neurobiol. 55, 4870–4884.
10.
HuangY.N., YangL.Y., GreigN.H., WangY.C., LaiC.C., and WangJ.Y. (2018). Neuroprotective effects of pifithrin-alpha against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. Sci. Rep. 8, 2368.
11.
LiuY.L., YuanF., YangD., XuZ.M., JingY., YangG.Y., GengZ., XiaW.L., and TianH.L. (2018). Adjudin attenuates cerebral edema and improves neurological function in mice with experimental traumatic brain injury. J. Neurotrauma. Epub ahead of. print.
12.
SzallasiA., CortrightD.N., BlumC.A., and EidS.R. (2007). The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6, 357–372.
13.
AmantiniC., MoscaM., NabissiM., LucciariniR., CaprodossiS., ArcellaA., GiangasperoF., and SantoniG. (2007). Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem. 102, 977–990.
14.
LamP.M., HainsworthA.H., SmithG.D., OwenD.E., DaviesJ., and LambertD.G. (2007). Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca(2+)](i), initiates neurotransmitter release and promotes delayed cell death. J. Neurochem. 102, 801–811.
15.
TothA., BoczanJ., KedeiN., LizaneczE., BagiZ., PappZ., EdesI., CsibaL., and BlumbergP.M. (2005). Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res. 135, 162–168.
16.
MiyanoharaJ., ShirakawaH., SanpeiK., NakagawaT., and KanekoS. (2015). A pathophysiological role of TRPV1 in ischemic injury after transient focal cerebral ischemia in mice. Biochem. Biophys. Res. Commun. 467, 478–483.
17.
MezeyE., TothZ.E., CortrightD.N., ArzubiM.K., KrauseJ.E., EldeR., GuoA., BlumbergP.M., and SzallasiA. (2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U. S. A. 97, 3655–3660.
18.
GolechS.A., McCarronR.M., ChenY., BembryJ., LenzF., MechoulamR., ShohamiE., and SpatzM. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132, 87–92.
19.
MarroneM.C., MorabitoA., GiustizieriM., ChiurchiuV., LeutiA., MattioliM., MarinelliS., RigantiL., LombardiM., MuranaE., TotaroA., PiomelliD., RagozzinoD., OddiS., MaccarroneM., VerderioC., and MarinelliS. (2017). TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat. Commun. 8, 15292.
20.
HakimizadehE., ShamsizadehA., RoohbakhshA., ArababadiM.K., HajizadehM.R., ShariatiM., RahmaniM.R., and AllahtavakoliM. (2017). Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model. Fundam. Clin. Pharmacol. 31, 420–428.
21.
ObermeierB., DanemanR., and RansohoffR.M. (2013). Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584–1596.
22.
ZhaoZ. and ZlokovicB.V. (2017). Remote control of BBB: a tale of exosomes and microRNA. Cell Res. 27, 849–850.
23.
LvJ., HuW., YangZ., LiT., JiangS., MaZ., ChenF., and YangY. (2018). Focusing on claudin-5: a promising candidate in the regulation of BBB to treat ischemic stroke. Prog. Neurobiol. 161, 79–96.
24.
AbbottN.J., RonnbackL., and HanssonE. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53.
25.
TokluH.Z. and TumerN. (2015). Oxidative stress, brain edema, blood-brain barrier permeability, and autonomic dysfunction from traumatic brain injuryin: Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. KobeissyF.H.(ed). Taylor & Francis Group, LLC.: Boca Raton FL.
26.
YangT., KongB., GuJ.W., KuangY.Q., ChengL., YangW.T., XiaX., and ShuH.F. (2014). Anti-apoptotic and anti-oxidative roles of quercetin after traumatic brain injury. Cell. Mol. Neurobiol. 34, 797–804.
27.
ThalS.C. and NeuhausW. (2014). The blood-brain barrier as a target in traumatic brain injury treatment. Arch. Med. Res. 45, 698–710.
28.
XuZ.M., YuanF., LiuY.L., DingJ., and TianH.L. (2017). Glibenclamide attenuates blood-brain barrier disruption in adult mice after traumatic brain injury. J. Neurotrauma, 34, 925–933.
29.
LippmannE.S., AzarinS.M., KayJ.E., NesslerR.A., WilsonH.K., Al-AhmadA., PalecekS.P., and ShustaE.V. (2012). Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30, 783–791.
30.
BlanchetteM. and DanemanR. (2015). Formation and maintenance of the BBB. Mech. Dev. 138, 8–16.
31.
HuD.E., EastonA.S., and FraserP.A. (2005). TRPV1 activation results in disruption of the blood-brain barrier in the rat. Br. J. Pharmacol. 146, 576–584.
32.
NitoC., KamadaH., EndoH., NarasimhanP., LeeY.S., and ChanP.H. (2012). Involvement of mitogen-activated protein kinase pathways in expression of the water channel protein aquaporin-4 after ischemia in rat cortical astrocytes. J. Neurotrauma, 29, 2404–2412.
33.
AhmedS.M., RzigalinskiB.A., WilloughbyK.A., SitterdingH.A., and EllisE.F. (2000). Stretch-induced injury alters mitochondrial membrane potential and cellular ATP in cultured astrocytes and neurons. J. Neurochem. 74, 1951–1960.
34.
ChenJ., SanbergP.R., LiY., WangL., LuM., WillingA.E., Sanchez-RamosJ., and ChoppM. (2001). Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke, 32, 2682–2688.
35.
SalvadorE., BurekM., and ForsterC.Y. (2015). Stretch and/or oxygen glucose deprivation (OGD) in an in vitro traumatic brain injury (TBI) model induces calcium alteration and inflammatory cascade. Front. Cell. Neurosci. 9, 323.
36.
DeckerT. and Lohmann-MatthesM.L. (1988). A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods, 115, 61–69.
37.
Rosas-HernandezH., CuevasE., Escudero-LourdesC., LantzS.M., SturdivantN.M., ImamS.Z., SarkarS., SlikkerW.Jr., PauleM.G., BalachandranK., and AliS.F. (2018). Characterization of uniaxial high-speed stretch as an in vitro model of mild traumatic brain injury on the blood-brain barrier. Neurosci. Lett. 672, 123–129.
38.
YuanF., XuZ.M., LuL.Y., NieH., DingJ., YingW.H., and TianH.L. (2016). SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-kappaB p65 acetylation and activation. J. Neurochem. 136, 581–593.
39.
JiangL., ZhongJ., DouX., ChengC., HuangZ., and SunX. (2015). Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury. Neuroscience, 301, 375–383.
40.
YurukerV., NazirogluM., and SenolN. (2015). Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: possible involvement of TRPM2 channels. Metab. Brain Dis. 30, 223–231.
41.
OrreniusS., ZhivotovskyB., and NicoteraP. (2003). Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 4, 552–565.
42.
SunZ., HanJ., ZhaoW., ZhangY., WangS., YeL., LiuT., and ZhengL. (2014). TRPV1 activation exacerbates hypoxia/reoxygenation-induced apoptosis in H9C2 cells via calcium overload and mitochondrial dysfunction. Int. J. Mol. Sci. 15, 18362–18380.
43.
LiuY.L., XuZ.M., YangG.Y., YangD.X., DingJ., ChenH., YuanF., and TianH.L. (2017). Sesamin alleviates blood-brain barrier disruption in mice with experimental traumatic brain injury. Acta Pharmacol. Sin. 38, 1445–1455.
44.
JiangJ.Y., LyethB.G., KapasiM.Z., JenkinsL.W., and PovlishockJ.T. (1992). Moderate hypothermia reduces blood-brain barrier disruption following traumatic brain injury in the rat. Acta Neuropathol. 84, 495–500.
45.
ShlosbergD., BeniflaM., KauferD., and FriedmanA. (2010). Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 6, 393–403.
46.
ScholzM., CinatlJ., Schadel-HopfnerM., and WindolfJ. (2007). Neutrophils and the blood-brain barrier dysfunction after trauma. Med. Res. Rev. 27, 401–416.
47.
YangJ., LiuX., BhallaK., KimC.N., IbradoA.M., CaiJ., PengT.I., JonesD.P., and WangX. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 275, 1129–1132.
48.
LuoX., BudihardjoI., ZouH., SlaughterC., and WangX. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481–490.
49.
CoryS. and AdamsJ.M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2, 647–656.
50.
YangE. and KorsmeyerS.J. (1996). Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386–401.
51.
LiuT., WangG., TaoH., YangZ., WangY., MengZ., CaoR., XiaoY., WangX. and ZhouJ. (2016). Capsaicin mediates caspases activation and induces apoptosis through P38 and JNK MAPK pathways in human renal carcinoma. BMC Cancer, 16, 790.
52.
SanchezA.M., Malagarie-CazenaveS., OleaN., VaraD., ChiloechesA., and Diaz-LaviadaI. (2007). Apoptosis induced by capsaicin in prostate PC-3 cells involves ceramide accumulation, neutral sphingomyelinase, and JNK activation. Apoptosis, 12, 2013–2024.
53.
ShiY. (2004). Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci. 13, 1979–1987.
54.
CaoJ., ChenJ., XieL., WangJ., FengC., and SongJ. (2015). Protective properties of sesamin against fluoride-induced oxidative stress and apoptosis in kidney of carp (Cyprinus carpio) via JNK signaling pathway. Aquat. Toxicol. 167, 180–190.
55.
ChengG., KongR.H., ZhangL.M., and ZhangJ.N. (2012). Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br. J. Pharmacol. 167, 699–719.
56.
UnterbergA.W., StoverJ., KressB., and KieningK.L. (2004). Edema and brain trauma. Neuroscience, 129, 1021–1029.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
